Display options
Cite
Zhou N, Zhu Y, Zhang P, et al. Imperatorin derivative OW1 inhibits the upregulation of TGF-β and MMP-2 in renovascular hypertension-induced cardiac remodeling. Exp Ther Med. 2016;11(5):1748-1754doi: 10.3892/etm.2016.3172.
Zhou, N., Zhu, Y., Zhang, P., Zhang, Y. U., Zhou, M., Wang, T., & He, L. (2016). Imperatorin derivative OW1 inhibits the upregulation of TGF-β and MMP-2 in renovascular hypertension-induced cardiac remodeling. Experimental and therapeutic medicine, 11(5), 1748-1754. https://doi.org/10.3892/etm.2016.3172
Zhou, Nan, et al. "Imperatorin derivative OW1 inhibits the upregulation of TGF-β and MMP-2 in renovascular hypertension-induced cardiac remodeling." Experimental and therapeutic medicine vol. 11,5 (2016): 1748-1754. doi: https://doi.org/10.3892/etm.2016.3172
Zhou N, Zhu Y, Zhang P, Zhang YU, Zhou M, Wang T, He L. Imperatorin derivative OW1 inhibits the upregulation of TGF-β and MMP-2 in renovascular hypertension-induced cardiac remodeling. Exp Ther Med. 2016 May;11(5):1748-1754. doi: 10.3892/etm.2016.3172. Epub 2016 Mar 15. PMID: 27168797; PMCID: PMC4840669.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2016 May;11(5):1748-1754. doi: 10.3892/etm.2016.3172. Epub 2016 Mar 15.

Imperatorin derivative OW1 inhibits the upregulation of TGF-β and MMP-2 in renovascular hypertension-induced cardiac remodeling.

Experimental and therapeutic medicine

Nan Zhou, Yaning Zhu, Peng Zhang, Y U Zhang, Mingyao Zhou, Tao Wang, Langchong He

Affiliations

  1. Department of Pharmacy, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China.
  2. Institute of Material Medica, School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
  3. Xi'an Medical Emergency Center, Xi'an, Shaanxi 710061, P.R. China.

PMID: 27168797 PMCID: PMC4840669 DOI: 10.3892/etm.2016.3172

Abstract

Chronic hypertension induces vascular and cardiac remodeling. OW1 is a novel imperatorin derivative that was previously reported to inhibit vascular remodeling and improve kidney function affected by hypertension. In the present study, the effect of OW1 on the cardiac remodeling induced by hypertension was investigated. OW1 inhibited vascular smooth muscle cell (VSMC) proliferation and the phenotypic modulation of VSMCs induced by angiotensin II (Ang II). The OW1-induced vasodilatation of rat cardiac arteries was evaluated in vitro. Renovascular hypertensive rats were developed using the two-kidney one-clip method and treated with OW1 (40 or 80 mg/kg/day) or nifedipine (30 mg/kg per day) for 5 weeks. OW1 markedly reduced the systolic and diastolic blood pressure compared with that in the hypertension group or the respective baseline value during the first week. OW1 also reduced cardiac weight, and the concentrations of Ang II, aldosterone and transforming growth factor-β1 (TGF-β1). Histological examination demonstrated that OW1 exerted an inhibitory effect on vascular and cardiac remodeling. These inhibitory effects were associated with decreased cardiac levels of Ang II, matrix metalloproteinase-2 and TGF-β

Keywords: OW1; blood pressure; cardiac remodeling; imperatorin derivative; two-kidney one-clip hypertensive rats

References

  1. Cardiovasc Res. 2004 Aug 15;63(3):423-32 - PubMed
  2. Int J Cardiol. 2001 Jul;79(2-3):277-86 - PubMed
  3. Am Heart J. 1992 Sep;124(3):700-9 - PubMed
  4. Physiol Rev. 2007 Oct;87(4):1285-342 - PubMed
  5. Arterioscler Thromb. 1991 Nov-Dec;11(6):1660-6 - PubMed
  6. Circ Res. 1993 Sep;73(3):413-23 - PubMed
  7. Mol Cell Biochem. 2008 Oct;317(1-2):43-50 - PubMed
  8. J Clin Invest. 2002 Mar;109(6):787-96 - PubMed
  9. Lancet. 2006 Jan 28;367(9507):356-67 - PubMed
  10. Arterioscler Thromb Vasc Biol. 1999 Jul;19(7):1623-9 - PubMed
  11. J Am Coll Cardiol. 2002 Apr 17;39(8):1384-91 - PubMed
  12. J Hypertens. 1998 Jul;16(7):1031-41 - PubMed
  13. J Clin Invest. 2007 Mar;117(3):568-75 - PubMed
  14. Am J Physiol Regul Integr Comp Physiol. 2008 Sep;295(3):R741-50 - PubMed
  15. Hypertension. 2008 Aug;52(2):195-200 - PubMed
  16. Pharmacol Ther. 2006 Sep;111(3):771-91 - PubMed
  17. Am J Physiol Heart Circ Physiol. 2007 Apr;292(4):H1847-60 - PubMed
  18. J Asian Nat Prod Res. 2014;16(3):304-11 - PubMed
  19. Int J Cardiol. 2013 Apr 30;165(1):165-73 - PubMed
  20. Circulation. 2005 Jul 26;112(4):544-52 - PubMed
  21. J Vasc Res. 2005 Sep-Oct;42(5):415-23 - PubMed
  22. Atherosclerosis. 2008 Jun;198(2):320-31 - PubMed
  23. Circulation. 2002 Sep 17;106(12):1543-9 - PubMed
  24. Basic Res Cardiol. 2008 Sep;103(5):431-43 - PubMed
  25. Circ Res. 1986 Dec;59(6):633-44 - PubMed
  26. Clin Exp Pharmacol Physiol. 2010 Apr;37(4):477-81 - PubMed
  27. Am J Physiol. 1990 Aug;259(2 Pt 2):H610-8 - PubMed
  28. Congest Heart Fail. 2002 May-Jun;8(3):132-40 - PubMed
  29. Cardiovasc Res. 1998 Jul;39(1):89-105 - PubMed
  30. Cardiovasc Res. 2006 Feb 15;69(3):688-96 - PubMed
  31. Growth Regul. 1995 Jun;5(2):69-84 - PubMed
  32. J Biomed Sci. 2007 Nov;14(6):757-65 - PubMed
  33. Circulation. 1994 Jul;90(1):362-8 - PubMed
  34. Matrix Biol. 2012 May;31(4):261-70 - PubMed
  35. J Mol Cell Cardiol. 2006 Dec;41(6):989-97 - PubMed
  36. Exp Mol Pathol. 2013 Feb;94(1):1-9 - PubMed
  37. Clin Exp Pharmacol Physiol. 2014 Aug;41(8):571-8 - PubMed

Publication Types